<DOC>
	<DOCNO>NCT00002503</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . This may effective treatment prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness strontium radiation therapy treat patient prostate cancer refractory hormone therapy painful bone metastasis .</brief_summary>
	<brief_title>Strontium Compared With Radiation Therapy Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : I . Compare , randomize Phase III setting , subjective response rate , time progression , survival patient hormone-refractory prostate cancer painful osseous metastasis treat either strontium-89 palliative local radiotherapy . II . Compare quality life achieve two regimen . III . Determine toxicity morbidity treatment two regimen . IV . Compare cost effectiveness two regimen . OUTLINE : Randomized study . Arm I : Radioisotope therapy . Strontium-89 chloride , Strontium-89 . Arm II : Radiotherapy . Involved-field irradiation ( equipment unspecified ) . PROJECTED ACCRUAL : 200 patient enter 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven carcinoma prostate relapse subsequent chemical surgical castration and/or antiandrogen therapy Painful , unirradiated osseous metastasis require Documentation bone scan xray require Number extent metastasis determine accord Soloway fit grade 13 Prior hormonal therapy must last least 3 month must continue completion study No imminent paraplegia related metastasis No uncorrectable urinary incontinence PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 02 Hematopoietic : WBC great 3,500 Platelets great 150,000 Hepatic : Not specify Renal : Creatinine great 2.2 mg/dl ( 200 micromoles/liter ) Other : No calcium supplementation No second malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No restriction Endocrine therapy : Prior concurrent hormonal therapy require Radiotherapy : No prior strontium89 No prior hemibody totalbody irradiation Prior localfield irradiation bone metastases allow provide new site painful metastasis exist Surgery : Surgical castration allow</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>